



	Screening	Therapy														End of Study Visit	Follow Up Visit
Cycle No.		1				2		3	4	5	6	7	8	9	10		
Duration		28				28		28	28	28	28	28	28	28	28	28	
Relative day within cycle	≤ 28	1	8	15	22	1	15	1	-	1	-	1	-	-	1	1	
Tumor Assessment																	
CT or MRI of abdomen and pelvis <sup>h</sup>	X							X		X		X			X	X	X
CT of chest <sup>i</sup>	X																X
FDG-PET imaging	X					X <sup>j</sup>											
Fresh tumor biopsy for mutational analysis and exploratory biomarkers																	X

<sup>a</sup> After Cycle 7, patients will be seen every 3 cycles until the end of study

<sup>b</sup> Patients will take CP-868,596 continuously until they fulfill one of the criteria for study discontinuation

<sup>c</sup> Visits during the first 2 cycles: ± 3 days

<sup>d</sup> Visits from the 3rd cycle to the end of study: ± 5 days

<sup>e</sup> History should include site of primary tumor, metastatic sites, GIST histology, time of relapses, PDGFR mutation status, tumor Kit expression

<sup>f</sup> Only for WOCBP; Includes a serum pregnancy test at screening, urine pregnancy test on Day 1 of Cycle 1, and a serum pregnancy test at EOS visit

<sup>g</sup> The second sample for PK may be drawn anytime between days 15 and 28 of cycle 1

<sup>h</sup> After cycle 7, CT scans of the abdomen and pelvis will be done quarterly

<sup>i</sup> Chest CT will be done at baseline and thereafter at physician's discretion

<sup>j</sup> FDG-PET imaging can be done anytime between day 1 of cycle 2 and day 1 of cycle 3